ADGRA2

Across TCGA pan-cancer cohorts, ADGRA2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ADGRA2 data layer compared with 28 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ADGRA2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADGRA2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

UCEC, PDAC, and GBM are the cancer types where ADGRA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Quartile	All	0.808	1.000	.010	16	view →
PDAC	DFS	Median	All	0.603	0.347	.015	16	view →
GBM	DFS	Tertile	All	0.416	0.917	.024	9	view →
LUAD	DFS	Quartile	All	0.783	0.429	.012	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ADGRA2–UCEC (DFS)

Open the UCEC breakdown →